Grifols Completes Acquisition of European Healthcare Company Biotest:.

MANews-(C)2009-2022

Spain-based pharmaceutical and chemical manufacturer Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) has completed the acquisition of 100% of the share capital of Germany based Tiancheng Pharmaceutical Holdings AG, holding 89.88% of the ordinary shares and 1.08% of the preferred shares of European healthcare company Biotest AG, the company said.

The transaction values Biotest's capital at approximately EUR 1,600m (USD 1,709m) (Equity Value) and its market value at EUR 2,000m (USD 2,136m) (Enterprise Value).

The acquisition of Biotest AG enables Grifols to accelerate and expand its product portfolio, increase the availability of plasma therapies for patients, own the largest private European network of plasma centres with 87 centres, and drive revenue growth and margin expansion.

Following the completion of the Public Takeover Offer and the closing of the...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT